⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29633894 | 0.71 | — | — | |
| SCHEMBL30691872 | 0.71 | TRPA1 (0.58) | — | |
| SCHEMBL5050147 | 0.71 | TRPA1 (0.58) | — | |
| SCHEMBL15075855 | 0.71 | — | — | |
| SCHEMBL9926021 | 0.71 | TRPA1 (0.58) | — | |
| SCHEMBL379614 | 0.70 | TRPA1 (0.33) | — | |
| SCHEMBL8121626 | 0.70 | GSK3B (0.37) | — | |
| SCHEMBL379612 | 0.70 | TRPA1 (0.33) | — | |
| SCHEMBL24372060 | 0.69 | TRPA1 (0.32) | — | |
| Fluoride SCHEMBL28557472 | 0.69 | TRPA1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090208565-A1 | STABILIZED EXENDIN-4 COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2009-08-20 | — | — | US | claimed |
| US-20060194719-A1 | Stabilized exendin-4 compounds | ZEALAND PHARMA A/S (DK) | 2006-08-31 | — | — | US | claimed |
| EP-1546200-A2 | STABILIZED EXENDIN-4 COMPOUNDS | Zealand Pharma A/S (DK) | 2005-06-29 | — | — | EP | claimed |
| WO-2004035623-A2 | STABILIZED EXENDIN-4 COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2004-04-29 | — | — | WO | claimed |
| US-5948774-A | EXCELLENT ANTIBACTERIAL ACTIVITIES ON A BROAD RANGE OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA, ESPECIALLY STAPHYLOCOCCUS AUREUS AND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-09-07 | — | — | US | claimed |
| EP-0160252-B1 | Antibacterial compounds | Takeda Chemical Industries, Ltd. (JP) | 1992-08-26 | — | — | EP | claimed |
| US-4788185-A | Cephalosporin compounds | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-11-29 | — | — | US | claimed |
| US-20240238460-A1 | IMPROVED PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETING RADIOPHARMACEUTICALS AND USES THEREOF | TELIX PHARMACEUTICALS INNOVATIONS PTY LTD (AU) | 2024-07-18 | — | — | US | disclosed |
| US-12030866-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2024115733-A1 | FUSED PYRROLYL-SULFONAMIDE COMPOUNDS | REWIND THERAPEUTICS NV (BE) | 2024-06-06 | — | — | WO | disclosed |
| EP-4347558-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | ReWind Therapeutics NV (BE) | 2024-04-10 | — | — | EP | disclosed |
| EP-4347541-A2 | IMPROVED PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETING RADIOPHARMACEUTICALS AND USES THEREOF | Telix Pharmaceuticals (Innovations) Pty Ltd (AU) | 2024-04-10 | — | — | EP | disclosed |
| CN-117794898-A | 3-pyrrolylsulfonamide compounds as GPR17 antagonists | 瑞文德医疗公众有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-85105977-A | The preparation method of antimicrobial compounds | — | 1987-02-25 | — | — | CN | disclosed |
| CN-85105299-A | The preparation method of cephem compounds | — | 1987-01-07 | — | — | CN | disclosed |
| CN-85105988-A | The preparation method of cephem compounds | — | 1986-10-29 | — | — | CN | disclosed |
| CN-85105797-A | The preparation of antimicrobial compounds | — | 1986-08-27 | — | — | CN | disclosed |
| EP-0164113-A2 | 3-pyrazolo(1,5-a)pyridinium cephem compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1985-12-11 | — | — | EP | disclosed |
| EP-0164122-A2 | Cephem compounds | Takeda Chemical Industries, Ltd. (JP) | 1985-12-11 | — | — | EP | disclosed |
| EP-0160252-A2 | Antibacterial compounds | Takeda Chemical Industries, Ltd. (JP) | 1985-11-06 | — | — | EP | disclosed |